Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (ABCL) is a leader in antibody discovery, combining microfluidics and advanced data science to accelerate therapeutic development. This page consolidates all official announcements and analysis-worthy updates about the company's progress in biopharmaceutical innovation.
Investors and industry observers will find timely updates on clinical milestones, financial performance, and strategic collaborations. Our curated feed includes earnings reports, partnership announcements with pharmaceutical entities, regulatory developments, and technological advancements in ABCL's antibody screening platform.
The resource prioritizes clarity and accessibility, offering both high-level summaries for casual observers and detailed technical updates for research-focused professionals. Content types include quarterly financial disclosures, intellectual property updates, executive leadership changes, and progress reports on therapeutic candidates in development.
Bookmark this page for streamlined tracking of ABCL's contributions to oncology, infectious disease treatment, and autoimmune disorder research. Check regularly for verified updates on how the company's proprietary discovery platform continues reshaping biotherapeutic development timelines.
AbCellera (Nasdaq: ABCL) has announced a purchase agreement with Eli Lilly for the supply of up to 600,000 doses of the investigational drug bebtelovimab. The deal is valued at a minimum of $720 million and is contingent upon obtaining Emergency Use Authorization from the FDA. Testing confirms that bebtelovimab neutralizes the Omicron variant and its subvariants. This drug is part of AbCellera's rapid response to COVID-19, initiated in 2020, which also led to the development of bamlanivimab.
AbCellera (Nasdaq: ABCL) will report its full year 2021 financial results on February 24, 2022, after market close. The earnings conference call will commence at 2:00 p.m. PT (5:00 p.m. ET), with a live webcast available on AbCellera’s Investor Relations website. The company specializes in antibody development, partnering with various drug developers to enhance drug development efficiency.
AbCellera (Nasdaq: ABCL) announced changes in its Board of Directors, appointing Andrew W. Lo, Ph.D., as an independent director, while John Hamer, Ph.D., resigned. Dr. Lo, known for his innovative financial engineering and machine learning in drug development, will join the Audit and Compensation Committees. CEO Carl Hansen praised Dr. Lo's expertise in connecting financial structures with biomedical innovation. Hamer, who served since 2018, was acknowledged for his valuable contributions. These changes aim to enhance AbCellera's strategic direction in antibody therapy development.
AbCellera (Nasdaq: ABCL) announced an expanded Emergency Use Authorization (EUA) from the
AbCellera (Nasdaq: ABCL) has appointed Neil Aubuchon as the new Chief Commercial Officer, bringing over 20 years of experience from renowned biopharmaceutical firms like Amgen and Eli Lilly. His role will focus on enhancing the company's commercial strategy and optimizing partnership opportunities for antibody-based therapies.
CEO Carl Hansen expressed confidence in Aubuchon's ability to evaluate and grow their portfolio. This strategic leadership change promises to strengthen AbCellera's market position in the evolving landscape of drug development.
AbCellera (Nasdaq: ABCL) reported Q3 2021 revenue of $5.5 million, down from $9.4 million in Q3 2020, attributed to reduced milestone payments from COVID-19 treatments. The company experienced a net loss of $21.4 million or ($0.08) per share, worsening from a net loss of $2.7 million or ($0.02) per share last year. Despite these losses, AbCellera achieved significant growth in its program starts and partnerships, adding 17 new programs and bringing cumulative program starts to 69. The firm retains a strong liquidity position with $753.5 million in cash and marketable securities.
AbCellera (Nasdaq: ABCL) will participate in several upcoming virtual investor conferences, including the Credit Suisse 30th Annual Virtual Healthcare Conference on November 11 at 7:30 a.m. PT, the Stifel 2021 Virtual Healthcare Conference on November 16 at 10:20 a.m. PT, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, with a recording available on November 22. Live webcasts will be accessible via AbCellera’s Investor Relations website, allowing investors to engage with the company's strategic initiatives.
AbCellera (Nasdaq: ABCL) announced a purchase agreement with the U.S. government, facilitating the supply of 614,000 doses of bamlanivimab with etesevimab for COVID-19 treatment, worth a total of $1.29 billion. Lilly will provide at least 400,000 doses by December 31, 2021. This therapy has reportedly treated over 535,000 patients, potentially preventing more than 25,000 hospitalizations and saving over 10,000 lives. Bamlanivimab is also part of AbCellera's broader efforts to combat COVID-19.
AbCellera (Nasdaq: ABCL) will release its third quarter 2021 financial results on November 9, 2021, followed by an earnings call at 2:00 p.m. PT (5:00 p.m. ET). The live conference can be accessed through AbCellera’s Investor Relations website, where a replay will also be available. AbCellera is a technology firm that aids in the discovery and development of antibodies for drug development by collaborating with a range of pharmaceutical and biotechnology partners.
AbCellera (Nasdaq: ABCL) has partnered with Everest Medicines Limited to discover therapeutic antibodies for up to 10 selected targets, primarily in oncology. This multi-year collaboration aims to enhance Everest's drug pipeline by leveraging AbCellera’s advanced antibody discovery technology, including humanized antibodies and bispecifics. Everest will develop and commercialize the resulting antibodies, while AbCellera will receive research payments and potential royalties. This partnership seeks to accelerate the delivery of innovative therapies to patients in Asia and beyond.
